Evidence map›Paper›PMID 40439002›Full record

ArticleCancer medicine2025

Gene Expression Analysis of (Paired) Primary and Relapsed Wilms Tumor Samples to Unravel the Underlying Factors Driving Tumor Recurrence.

Alissa Groenendijk, Jarno Drost, Annelies M C Mavinkurve-Groothuis, Martine van Grotel, Geert O Janssens, Annemieke S Littooij, Alida F W van der Steeg, Marry M van den Heuvel-Eibrink, Lennart Kester, Ronald R de Krijger

Abstract read
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alissa GroenendijkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0001-6466-7785
Jarno DrostPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Annelies M C Mavinkurve-GroothuisPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Martine van GrotelPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Geert O JanssensPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Annemieke S LittooijPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Alida F W van der SteegPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Marry M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Lennart KesterPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Ronald R de KrijgerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to unravel underlying factors driving Wilms tumor (WT) recurrence and to build a prediction model for recurrence based on gene expression data of (paired) primary and relapsed WT samples. EXPERIMENTAL

designGene expression levels from seven paired primary and relapsed WT samples from patients treated in the Princess Máxima Center were compared among each other, as well as to matched primary WT samples of patients without recurrence (controls). The differential gene expression analysis results were run through ToppGene for functional enrichment. We built a 10-fold ridge regression model to predict relapse based on gene expression levels of the seven primary cases and all other available primary WT controls (n = 42).

resultsThe comparison of primary WT and paired relapses showed downregulation of genes involved in immune regulation among relapses and upregulation of cancer stem cell (CSC) regulation genes. Comparing these primary WT samples to matched controls, we observed that downregulated genes in primary samples of relapsed patients were related to stromal cells and muscle development, and upregulated genes were associated with CSCs. The prediction model revealed a sensitivity of 57.14% (95% CI: 14.29%-85.71%) and a specificity of 92.86% (95% CI: 83.33%-100%) when predicting WT relapse.

conclusionThe CSC pool could play a role in relapse through immune regulation and tumor propagation. Differentiation of CSCs into mesenchymal cells might attenuate the risk of relapse. Our prediction model might aid in selecting patients with an increased risk of relapse at primary diagnosis when externally validated.

Indexed as

Biomarkers, TumorGene Expression Regulation, NeoplasticKidney NeoplasmsNeoplasm Recurrence, LocalWilms TumorChildChild, PreschoolFemaleGene Expression ProfilingHumansInfantMaleNeoplastic Stem CellsPrognosisTranscriptomeBiomarkers, Tumor

Identifiers

PMID40439002
PMCPMC12120524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.